Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors

Stem Cells

Volumn 25, Issue 10, 2007, Pages 2660-2669

  Matsui, Hideto ^a   Shibata, Masaru ^a,b   Brown, Brian ^a   Labelle, Andrea ^a   Hegadorn, Carol ^a   Andrews, Chandler ^a   Hebbel, Robert P ^c   Galipeau, Jacques ^d   Hough, Christine ^a   Lillicrap, David ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Blood outgrowth endothelial cells; Ex vivo gene therapy; Hemophilia A; Lentivirus

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; LENTIVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBOMODULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; ENDOTHELIUM CELL; GENE THERAPY; GENETIC ENGINEERING; HEMOPHILIA A; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; STEM CELL;

ANIMALS; CELLS, CULTURED; DESENSITIZATION, IMMUNOLOGIC; DOGS; ENDOTHELIAL CELLS; FACTOR VIII; FEASIBILITY STUDIES; GENE THERAPY; GENETIC VECTORS; GRAFT SURVIVAL; HEMOPHILIA A; INJECTIONS, SUBCUTANEOUS; LENTIVIRUS; MICE; MICE, INBRED NOD; MICE, MUTANT STRAINS; MICE, SCID; RECOMBINANT FUSION PROTEINS; TISSUE SCAFFOLDS; TRANSDUCTION, GENETIC;

ANIMALIA; CYTOMEGALOVIRUS; LENTIVIRUS; MURINAE; MUS;

EID: 35348867348     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0699     Document Type: Article

References (46)

1. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984;312:326-330.
2. Chuah MK, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost 2004;30:249-256.
3. Hough C, Lillicrap D. Gene therapy for hemophilia: An imperative to succeed. J Thromb Haemost 2005;3:1195-1205.
4. Kay MA, High K. Gene therapy for the hemophilias. Proc Natl Acad Sci U S A 1999;96:9973-9975.
5. Kelley K, Verma I, Pierce GF. Gene therapy: Reality or myth for the global bleeding disorders community? Haemophilia 2002;8:261-267.
6. Powell JS, Ragni MV, White GC 2nd et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003;102:2038 -2045.
7. Van Damme A, Chuah MK, Collen D at al. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: Preclinical studies. Semin Thromb Hemost 2004;30:185-195.
8. VandenDriessche T, Collen D, Chuah MK. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther 2001;1:301-315.
9. Chuah MK, Schiedner G, Thorrez L et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003;101:1734-1743.
10. Thorrez L, VandenDriessche T, Collen D et al. Preclinical gene therapy studies for hemophilia using adenoviral vectors. Semin Thromb Hemost 2004;30:173-183.
11. Brown BD, Shi CX, Powell S et al. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 2004;103:804-810.
12. Brown BD, Shi CX, Rawle FE et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost 2004;2:111-118.
13. Moayeri M, Ramezani A, Morgan RA et al. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 2004;10:892-902.
14. VandenDriessche T, Vanslembrouck V, Goovaerts I et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci U S A 1999;96:10379-10384.
15. Kootstra NA, Matsumura R, Verma IM. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol Ther 2003;7:623-631.
16. Kang Y, Xie L, Tran DT et al. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood 2005;106:1552-1558.
17. Verhoeyen E, Wiznerowicz M, Olivier D et al. Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 2005;106:3386-3395.
18. Yang Y, Jooss KU, Su Q et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996;3:137-144.
19. Brown BD, Lillicrap D. Dangerous liaisons: The role of "danger" signals in the immune response to gene therapy. Blood 2002;100:1133-1140.
20. Lozier JN, Metzger ME, Donahue RE et al. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999;94:3968-3975.
21. VandenDriessche T, Collen D, Chuah MK. Biosafety of onco-retroviral vectors. Curr Gene Ther 2003;3:501-515.
22. Themis M, Waddington SN, Schmidt M et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 2005;12:763-771.
23. Chuah MK, Brems H, Vanslembrouck V et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther 1998;9:353-365.
24. Chuah MK, Van Damme A, Zwinnen H et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000;11:729-738.
25. Van Damme A, Chuah MK, Dell'accio F et al. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. Haemophilia 2003;9:94-103.
26. Van Damme A, Thorrez L, Ma L et al. Efficient Lentiviral Transduction And Improved Engraftment Of Human Bone Marrow Mesenchymal Cells. STEM CELLS 2006;24:896-907.
27. Roth DA, Tawa NE Jr, O'Brien JM et al. Factor VIII Transkaryotic Therapy Study Group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344:1735-1742.
28. Lin Y, Weisdorf DJ, Solovey A et al. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-77.
29. Lin Y, Chang L, Solovey A et al. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002;99:457-462.
30. VandenDriessche T, Thorrez L, Naldini L et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002;100:813-822.
31. Notley C, Killoran A, Cameron C et al. The canine factor VIII 3′-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Hum Gene Ther 2002;13:1583-1593.
32. Karolewski BA, Watson DJ, Parente MK et al. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum Gene Ther 2003;14:1287-1296.
33. Baekelandt V, Eggermont K, Michiels M et al. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther 2003;10:1933-1940.
34. Sastry L, Johnson T, Hobson MJ et al. Titering lentiviral vectors: Comparison of DNA, RNA and marker expression methods. Gene Ther 2002;9:1155-1162.
35. Laird PW, Zijderveld A, Linders K et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 1991;19:4293.
36. Shibata M, Rawle F, Labelle A et al. Characterization of canine factor VIII and quantitative determination in canine plasma. J Thromb Haemost 2005; 3(suppl 1):Abstr P0033.
37. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:612.
38. Smits PA, Kleppe LS, Witt TA et al. Distribution of circulation-derived endothelial progenitors following systemic delivery. Endothelium 2007;14:1-5.
39. Miller DG, Trobridge GD, Petek LM et al. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 2005;79:11434-11442.
40. Manno CS, Arruda VR, Pierce GF et al. Successful transduction of liver in hemophilia by AAV-FIX and limitation imposed by the host immune response. Nat Med 2006;12:342-347.
41. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCIDX1. Science 2003;302:415-419.
42. Otto MG, Schmidt M, Schwarzwaelder K et al. Correction of X-linked choronic granulomatous disease by gene therapy, augmented by insertional activation by MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-409.
43. Montini E, Cesana D, Schmidt M et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24:687-696.
44. Nilsson IM, Berntorp E, Lofqvist T et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
45. Jacquemin M, Neyrinck A, Hermanns MI et al. FVIII production by human lung microvascular endothelial cells. Blood 2006;108:515-517.
46. Shi Q, Wilcox DA, Fahs SA et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006;116:1974 -1982.